Drug Trial Radar · NCT02833350
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
Last checked: Nov 19, 2026Latest source record: Jun 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
578
Actual
Start
Sep 9, 2016
Primary completion
Jul 2, 2018
Study completion Jul 2, 2018
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).
Conditions
- Rheumatoid Arthritis
Interventions
GDC-0853Drug
Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
AdalimumabDrug
Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
Folic AcidDrug
Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
MTXDrug
Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
PlaceboDrug
Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)Time frame: Day 84
- Percentage of Participants With Adverse EventsTime frame: Day 1 up to 8 weeks after last dose (up to Week 20)
Locations
150 sites in 11 countries. Site status is shown where the registry gives one.
Pinnacle Research Group; Llc, Central
Anniston, Alabama
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona
Medvin Clinical Research
Covina, California
TriWest Research Associates, LLC
El Cajon, California
Saint Jude Heritage Medical Grp
Fullerton, California
Stanford University School of Medicine
Stanford, California
RASF-Clinical Research Center
Boca Raton, Florida
ZASA Clinical Research
Boynton Beach, Florida
Clinical Research of West Florida
Clearwater, Florida
InVentiv Health
Miami, Florida
Omega Research Consultants
Orlando, Florida
McIlwain Medical Group
Tampa, Florida
Institute of Arthritis Research
Idaho Falls, Idaho
Advanced Clinical Research
Meridian, Idaho
Medication Management
Greensboro, North Carolina
Oregon Health and Science University
Portland, Oregon
Clinical Research Center of Reading
Wyomissing, Pennsylvania
Metroplex Clinical Research
Dallas, Texas
Baylor Research Inst.
Dallas, Texas
Accurate Clinical Management - VO
Houston, Texas
Accurate Clinical Research
Houston, Texas
Crossroads Clinical Research, LLC
Victoria, Texas
Danville Orthopedic Clinic, Inc.; Research Department
Danville, Virginia
Instituto de Investigaciones Clinicas-Mar del Plata
Buenos Aires, Argentina
Organizacion Medica de Investigacion
Buenos Aires, Argentina
Hospital Italiano
Buenos Aires, Argentina
APRILLUS
Buenos Aires, Argentina
Instituto centenario
Buenos Aires, Argentina
Centro de Investigacion en Enfermedades Reumaticas CIER
Ciudad Autonoma Buenos Aires, Argentina
Expertia S.A- Mautalen Salud e Investigación
Ciudad Autonoma Buenos Aires, Argentina
CCBR - Buenos Aires - AR; AxisMed SRL
Ciudad Autonoma Buenos Aires, Argentina
ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas
Córdoba, Argentina
Hospital Italiano de La Plata
La Plata, Argentina
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, Argentina
Instituto de Investigaciones Clínicas Quilmes
Quilmes, Argentina
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
San Juan, Argentina
Centro Medico Privado de Reumatologia; Reumathology
San Miguel, Argentina
CIP - Centro Internacional de Pesquisa; Pesquisa Clinica
Goiânia, Goiás, Brazil
Centro Mineiro de Pesquisa - CMIP
Juiz de Fora, Minas Gerais, Brazil
Edumed - Educação e Saúde SA
Curitiba, Paraná, Brazil
Showing 40 of 150 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.